[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cybin Inc (HELP)

Cybin Inc (HELP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 286,041
  • Shares Outstanding, K 51,632
  • Annual Sales, $ 0 K
  • Annual Income, $ -81,310 K
  • EBIT $ -118 M
  • EBITDA $ -117 M
  • 60-Month Beta 0.80
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.95

Options Overview Details

View History
  • Implied Volatility 89.98% (-16.76%)
  • Historical Volatility 81.86%
  • IV Percentile 13%
  • IV Rank 6.09%
  • IV High 353.04% on 03/02/26
  • IV Low 72.91% on 01/22/26
  • Expected Move (DTE 8) 0.77 (14.33%)
  • Put/Call Vol Ratio 0.34
  • Today's Volume 1,690
  • Volume Avg (30-Day) 1,617
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 34,603
  • Open Int (30-Day) 26,337
  • Expected Range 4.58 to 6.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.04
  • Number of Estimates 1
  • High Estimate $-1.04
  • Low Estimate $-1.04
  • Prior Year $-1.02
  • Growth Rate Est. (year over year) -1.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.85 +10.10%
on 04/21/26
6.26 -14.68%
on 04/27/26
+0.09 (+1.71%)
since 04/07/26
3-Month
4.29 +24.48%
on 03/30/26
8.55 -37.54%
on 03/04/26
-0.64 (-10.70%)
since 02/06/26
52-Week
4.29 +24.48%
on 03/30/26
9.83 -45.68%
on 07/01/25
-0.87 (-14.01%)
since 05/07/25

Most Recent Stories

More News
CORRECTION: Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health 

NEW YORK & TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- In a release issued under the same headline on April 28, 2026, by Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP), please note references to Veterans...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference

Eric So, Interim CEO, to appear on panel entitled “The Next Wave of Health Innovation,” on May 4, 2026 NEW YORK and TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP)...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health 

Collaboration with leading mental health organization to support HLP003 Phase 3 recruitment and expand outreach in veteran communities following landmark Executive Order on breakthrough mental health treatments...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan

Addition of globally recognized leaders in translational science and clinical development as the Company advances its pipeline towards key inflection points NEW YORK and TORONTO, April 23, 2026...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions

NEW YORK and TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma Announces Chief Executive Officer Transition; Eric So to Resume Role as Interim Chief Executive Officer

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17,...

HELP : 5.34 (-3.61%)
HELP.NE : 7.2700 (-2.42%)
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs

Dr. Kramer’s 25 years’ of experience in neuroscience and proven track record leading global medical launch neuropsychiatry teams will strengthen scientific and clinical engagement NEW YORK and...

HELP : 5.34 (-3.61%)
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer

Proven human resources and organizational strategist brings more than two decades of leadership across the pharmaceutical industry Appointment supports Helus Pharma’s continued maturation as the company...

HELP : 5.34 (-3.61%)
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END

HELP : 5.34 (-3.61%)
BWAY : 16.71 (+1.83%)
ACHC : 24.46 (-3.32%)
AIFF : 1.9000 (-1.55%)
JNJ : 222.51 (-0.94%)
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder

Statistically significant (p

HELP : 5.34 (-3.61%)

Business Summary

Helus Pharma is a clinical stage pharmaceutical company. Its lead candidate includes HLP003 and HLP004. Helus Pharma, formerly known as Cybin Inc., is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 5.74
2nd Resistance Point 5.61
1st Resistance Point 5.47
Last Price 5.34
1st Support Level 5.20
2nd Support Level 5.07
3rd Support Level 4.93

See More

52-Week High 9.83
Fibonacci 61.8% 7.71
Fibonacci 50% 7.06
Fibonacci 38.2% 6.41
Last Price 5.34
52-Week Low 4.29

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.